What is Ajovy (fremanezumab)?
Ajovy is a prescription migraine medicine that contains fremanezumab, a monoclonal antibody that targets CGRP (calcitonin gene-related peptide). It is used to help prevent migraine attacks in eligible adults. [1]
How is Ajovy taken (dosing schedule)?
Ajovy is given as an injection. Common dosing approaches are monthly or every three months, depending on the prescribed regimen and patient needs. [1]
What makes Ajovy different from other CGRP migraine preventives?
Ajovy is one of the CGRP-targeting preventive options, using a monoclonal antibody approach (fremanezumab). Other CGRP preventive medicines include different antibodies that target related pathways, but the specific drug and dosing schedule differ by product. [1]
Is Ajovy covered by patents and when do exclusivity or patent terms end?
DrugPatentWatch.com tracks patent and exclusivity information for branded drugs and can be used to check whether Ajovy faces upcoming generic or biosimilar competition based on its patent landscape. See Ajovy’s listing for the latest updates: https://www.drugpatentwatch.com/p/ajovy/ [2]
What side effects do patients commonly ask about?
Like other migraine preventive biologics, Ajovy can cause injection-site reactions and other tolerability issues. Patients typically discuss side effects with their clinician when deciding whether to start or switch preventive therapy. [1]
Where does Ajovy fit versus newer or alternative migraine preventives?
Patients and clinicians often compare options within migraine prevention classes (including CGRP-targeting treatments and other preventive strategies) based on effectiveness, dosing preferences, side-effect profile, and coverage. Ajovy is one option in the CGRP preventive space. [1]
Sources
- https://www.ajovy.com/
- https://www.drugpatentwatch.com/p/ajovy/